|
|
Enron Mail |
Francois and Kent,
Hope this proposal reaches you in time for consideration for the upcoming FMA-European meeting. I normally don't like to commit myself to a proposal but in this case I'm very comfortable doing so in light of the status of the project. As you will see this "clinical" paper is a study of strategy formulation in a very innovative company that uses financial derivatives in conjunction with real asset investments. The firm, Enron, has been the most innovative company in America for more than five years now and has expanded its strategy abroad. We have the unique opportunity to document the firm's strategy from the inside with my co-authors being members of the corporate research staff that manage the pricing of the energy derivatives in which the firm makes a market, as well as provide the analysis upon which firm risk positions are managed. Although, specific Enron projects have been documented and published, noone has captured the story of the company visionaries that formulated and executed the firm's business strategy. Of course, what makes the story of particular interest to finance scholars is the fact that the strategy hinges in very important ways on financial innovations. This is going to be a very informative and fun story to tell and I hope to bring along my colleagues from Enron to Paris for the meeting. Thanks for asking me to join the program advisory board and I look forward to your comments on the attached proposal. Sincerely yours, John - Enron Transformation Paper.doc John D. Martin Carr P. Collins Chair in Finance Finance Department Baylor University PO Box 98004 Waco, TX 76798 254-710-4473 (Office) 254-710-1092 (Fax) J_Martin@Baylor.edu web: http://hsb.baylor.edu/html/martinj/home.html
|